Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1293-1298

  Braconi, Chiara ^a   Bracci, R ^a   Bearzi, I ^a   Bianchi, F ^a   Sabato, S ^a   Mandolesi, A ^a   Belvederesi, L ^a   Cascinu, S ^a   Valeri, N ^a   Cellerino, R ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

GIST; IGF1; IGF2

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 46149111291     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn040     Document Type: Article

References (40)

1. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
2. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710.
3. Zhu MJ, Ou WB, Fletcher CD et al. KIT oncoprotein interactions in gastrointestinal stromal tumors: Therapeutic relevance. Oncogene 2007; 26: 6386-6395.
4. Yu H, Rohan T, Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489.
5. Roy RN, Gerulath AH, Cecutti A, Bhavnani BR. Loss of IGF-II imprinting in endometrial tumors: Overexpression in carcinosarcoma. Cancer Lett 2000; 153: 67-73.
6. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133-137.
7. Renehan AG, Zwahlen M, Minder C et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353.
8. Severi G, Morris HA, MacInnis RJ et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1137-1141.
9. Baglietto L, English DR, Hopper JL et al. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 763-768.
10. Allen NE, Key TJ, Appleby PN et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: Results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007; 16: 1121-1127.
11. Weiss JM, Huang WY, Rinaldi S et al. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 2007; 121: 2267-2273
12. Otani T, Iwasaki M, Sasazuki S et al. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: The Japan public health center-based prospective study. Int J Cancer 2007; 120: 2007-2012.
13. Gunter MJ, Hoover DR, Yu H et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 2008; 68: 329-337.
14. Wei EK, Ma J, Pollak MN et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005; 14: 850-855.
15. Ma J, Pollak MN, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-625.
16. Sekharam M, Zhao H, Sun M et al. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2003; 63: 7708-7716.
17. Shi B, Sepp-Lorenzino L, Prisco M et al. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282: 32582-32590.
18. Ealey KN, Xuan W, Lu S, Archer MC. Colon-carcinogenesis in liver-specific IGF-I-deficient (LID) mice. Int J Cancer 2008; 122: 472-476.
19. Escobar GA, Robinson WA, Nydam TL et al. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: A case report. BMG Cancer 2007; 7: 13.
20. Guiteau J, Fanucchi M, Folpe A et al. Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. Am Surg 2006; 72: 1225-1230.
21. Fukuda I, Hizuka N, Ishikawa Y et al. Clinical features of insulin-liKe growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 2006; 16: 211-216.
22. Hamberg P, de Jong FA, Boonstra JG et al. Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinip. J Clin Oncol 2006; 24: E30-e31.
23. Singh R, Grey A, Miller M et al. Non-hyperinsulinemic hypoglycemia in a patient with a gastrointestinal stromal tumor. Eur J Intern Med 2006; 17: 127-129.
24. Rikhof B, Van Den BG. Van Der Graaf WT. Non-islet cell tumour hypoglycaemia in a patient with a gastrointestinal stromal tumour. Acta Oncol 2005; 44: 764-766.
25. Pink D, Schoeler D, Lindner T et al. Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: A report of two cases. J Clin Oncol 2005; 23: 6809-6811.
26. Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004; 14: 337-375.
27. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465.
28. Nilsson B, Sjolund K, Kindblom LG et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96: 1656-1658.
29. Imamura M, Yamamoto H, Nakamura N et al. Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol 2007; 20: 529-537.
30. Takahashi R, Tanaka S, Kitadai Y et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003; 64: 266-274.
31. Takahashi R, Tanaka S, Hiyama T et al. Hypoxia-inducible tactor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep 2003; 10: 797-802.
32. Cappuzzo F, Toschi L, Tallini G et al. Insulin-like growth factor receptor 1 (IGER-1) is significantly associated with longer survival in non-small-cell lung cancer patents treated with gefitinib. Ann Oncol 2006; 17: 1120-1127.
33. Mulligan AM, O'malley FP, Ennis M et al. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007; 106: 36-46.
34. Cardillo MR, Monti S, Di SF et al. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-1) expression in prostatic cancer. Anticancer Res 2003; 23: 3825-3835.
35. Valentinis B, Romano G, Peruzzi F et al. Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem 1999; 274: 12423-12430.
36. Ahlen J, Wejde J, Brosjo O et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 2005; 11: 206-216.
37. Tam C, Skorobogatko YV, Taguchi T et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006; 66: 5477-5486.
38. Lasota J, Stachura J, Miettinen M. GISTs with POGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 2006; 86: 94-100.
39. Braconi C, Bracci R, Bearzi I et al. KIT and PDGFR [alpha] mutations in 104 patients with gastrointestinal stromal tumors (GISTs): A population-based study. Ann Oncol 2008, Jan 10, Epud ahead of printing.
40. Manara MC, Landuzzi L, Nanni P et al. Preclinical in vivo study of new insulin-like growth factor-1 receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007; 13: 1322-1330.